Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
16 hedge funds and large institutions have $18M invested in Ambrx Biopharma Inc in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
14% more funds holding
Funds holding: 14 → 16 (+2)
1.23% less ownership
Funds ownership: 44.36% → 43.13% (-1.2%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
60% less capital invested
Capital invested by funds: $45.4M → $18M (-$27.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$109K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$87.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$25K |
| 5 |
Millennium Management
New York
|
+$22.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$554K |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$325K |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$309K |
| 4 |
Norges Bank
Oslo,
Norway
|
-$165K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$5.66K |
AMAM Hedge Fund Activity: Q3 2022 in Review
16 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q3 2022, worth a combined $18M — down 60% from $45.4M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new AMAM positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $109K. The largest seller was Fidelity Investments, cutting an estimated $554K.
- 16 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q3 2022, up from 14 in Q2 2022.
- Funds reported $18M of Ambrx Biopharma Inc stock for Q3 2022, down 60% quarter-over-quarter.
- 4 funds opened new Ambrx Biopharma Inc positions in Q3 2022 and 2 closed out, a net change of +2 holders.
- The largest Ambrx Biopharma Inc buyer in Q3 2022 was Renaissance Technologies, an estimated $109K added.
- The largest Ambrx Biopharma Inc seller in Q3 2022 was Fidelity Investments, an estimated $554K sold.
Based on aggregated 13F filings for Q3 2022.